- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tudor Investment Corp ET AL Trims NeoGenomics, Inc. $NEO Stake
The hedge fund reduced its position in the medical research company by 46% in the third quarter.
Apr. 11, 2026 at 11:36am
Got story updates? Submit your updates here. ›
The reduction in ownership by a major hedge fund highlights the volatility surrounding NeoGenomics, but the company's critical role in cancer diagnostics remains steadfast.Fort Myers TodayTudor Investment Corp ET AL, a hedge fund, reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 46% in the third quarter, according to a recent disclosure with the Securities and Exchange Commission. The fund now owns 375,351 shares of the medical research company's stock, worth $2.9 million.
Why it matters
This move by a major institutional investor signals potential shifts in sentiment around NeoGenomics, which provides cancer-focused genetic and molecular testing services. Tracking changes in institutional ownership can provide insights into the market's outlook on a company's prospects.
The details
In the third quarter, Tudor Investment Corp ET AL sold 320,361 shares of NeoGenomics, reducing its total position to 375,351 shares. The fund now owns 0.29% of the company's outstanding stock. Several other hedge funds and institutional investors also made changes to their NeoGenomics holdings during the quarter, with some increasing and others decreasing their positions.
- The stake reduction occurred in the third quarter of 2026.
The players
Tudor Investment Corp ET AL
A hedge fund that has reduced its position in NeoGenomics, Inc.
NeoGenomics, Inc.
A leading provider of cancer-focused genetic and molecular testing services, traded on the Nasdaq under the symbol NEO.
The takeaway
This move by a major institutional investor highlights the ongoing shifts in sentiment around NeoGenomics, a company that plays a crucial role in the detection, prognosis, and treatment of various types of cancer. Tracking changes in institutional ownership can provide valuable insights into the market's outlook on the company's prospects.
